Literature DB >> 29484435

Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells.

Xiaofeng Wang1, Jinting He2, Xiaoming Zhao2, Tianyang Qi3, Tianfu Zhang1, Chenfei Kong3.   

Abstract

Epithelial-mesenchymal transition (EMT) is one of the major processes that contribute to the occurrence of cancer metastasis. EMT has been associated with the development of oral cancer. Syndecan‑1 (SDC1) is a key cell‑surface adhesion molecule and its expression level inversely correlates with tumor differentiation and prognosis. In the present study, we aimed to determine the role of SDC1 in oral cancer progression and investigate the molecular mechanisms through which SDC1 regulates the EMT and invasiveness of oral cancer cells. We demonstrated that basal SDC1 expression levels were lower in four oral cancer cell lines (KB, Tca8113, ACC2 and CAL‑27), than in normal human periodontal ligament fibroblasts. Ectopic overexpression of SDC1 resulted in morphological transformation, decreased expression of EMT‑associated markers, as well as decreased migration, invasiveness and proliferation of oral cancer cells. In contrast, downregulation of the expression of SDC1 caused the opposite results. Furthermore, the knockdown of endogenous SDC1 activated the extracellular signal‑regulated kinase (ERK) cascade, upregulated the expression of Snail and inhibited the expression of E‑cadherin. In conclusion, our findings revealed that SDC1 suppressed EMT via the modulation of the ERK signaling pathway that, in turn, negatively affected the invasiveness of human oral cancer cells. Our results provided useful evidence about the potential use of SDC1 as a molecular target for therapeutic interventions in human oral cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29484435     DOI: 10.3892/or.2018.6271

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  PADI4‑mediated epithelial‑mesenchymal transition in lung cancer cells.

Authors:  Meiyan Liu; Yang Qu; Xue Teng; Ying Xing; Dandan Li; Chunhong Li; Li Cai
Journal:  Mol Med Rep       Date:  2019-02-19       Impact factor: 2.952

2.  Loss of expression of Syndecan-1 is associated with Tumor Recurrence, Metastatic Potential, and Poor Survival in patients with Colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi
Journal:  Pak J Med Sci       Date:  2021 Jan-Feb       Impact factor: 1.088

Review 3.  Proteoglycans as Mediators of Cancer Tissue Mechanics.

Authors:  Anna Barkovskaya; Alexander Buffone; Martin Žídek; Valerie M Weaver
Journal:  Front Cell Dev Biol       Date:  2020-11-30

4.  circCEP128 Knockdown Suppresses Bladder Cancer Progression via Regulating microRNA-515-5p/SDC1 Axis.

Authors:  Guanghui Cao; Chan Zhang; Xiangyong Tian; Gaopeng Jing; Xiaolin Zhou; Tianzhong Yan
Journal:  Cancer Manag Res       Date:  2021-03-29       Impact factor: 3.989

5.  Exploring the Molecular Crosstalk between Pancreatic Bud and Mesenchyme in Embryogenesis: Novel Signals Involved.

Authors:  Ilaria Guerriero; Maria Teresa De Angelis; Fulvio D'Angelo; Rita Leveque; Eleonora Savignano; Luca Roberto; Valeria Lucci; Pellegrino Mazzone; Simona Laurino; Giovanni Storto; Anna Nardelli; Alessandro Sgambato; Michele Ceccarelli; Mario De Felice; Elena Amendola; Geppino Falco
Journal:  Int J Mol Sci       Date:  2019-10-03       Impact factor: 5.923

6.  Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.

Authors:  Shaojun Wang; Xiaofei Zhang; Guimei Wang; Bin Cao; Hong Yang; Lipeng Jin; Mingjuan Cui; Yongjun Mao
Journal:  BMC Cancer       Date:  2019-11-29       Impact factor: 4.430

7.  SDC1 knockdown induces epithelial-mesenchymal transition and invasion of gallbladder cancer cells via the ERK/Snail pathway.

Authors:  Zixiang Liu; Hao Jin; Song Yang; Haiming Cao; Ziyan Zhang; Bo Wen; Shaobo Zhou
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.